TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03357419
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses.
Study: NCT05602727
Drug: MK-1942
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1942 oral capsule
Study: NCT05602727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT05550090
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were given 2 cycles of chemotherapy, including the chemotherapy recommended by the clinical treatment guidelines for advanced metastatic breast cancer, which can be combined with targeted or immune or endocrine therapy.
Study: NCT05834582
Drug: Epirubicin+Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin+Cyclophosphamide
Study: NCT05672082
Drug: [18F]DPA-714
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant received one injection of 200 MBq of \[18F\]DPA-714
Study: NCT04890522
Drug: Triprilimab(JS001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum 6 cycles for combined therapy and maintenance for up to 2 years.
Study: NCT06077916
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin is reconstituted and administered according to standard prescription indications in 250 mL saline solution
Study: NCT00004442
Drug: chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04939701
Drug: ASP0739
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT05704738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT05622916
Drug: Topical Ethanol Extract (Piper crocatum)
Normalized name: ethanol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
Study: NCT05622916
Drug: Trichloroacetic Acid Topical
Normalized name: trichloroacetic acid topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichloroacetic acid topical 90%
Study: NCT05043922
Drug: CYH33
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a Selective PI3Kα Inhibitor
Study: NCT04730193
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
Study: NCT04763083
Drug: NVG-111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles
Study: NCT06378684
Drug: Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study: NCT06378684
Drug: Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study: NCT05494957
Drug: New regimen(BdqCfzLzd+XY)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The basic regimen consists of bedaquiline, clofazimine, linezolid, and 2-3 drugs such as amikacin and tigecycline are selected according to the drug use history and in vitro culture drug sensitivity results to form the regimen, and the treatment period is usually more than 12 months, and the doses of various drugs are used for the regular drug use.
Study: NCT02699138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded sugar pill
Study: NCT04940338
Drug: Bromfenac Ophthalmic 0.09% Ophthalmic Solution
Normalized name: bromfenac ophthalmic 0.09% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical bromfenac (0.9 mg/mL) 2x daily 7 days before the surgery
Study: NCT04940338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical placebo (artificial tears substitute) 2x daily before the surgery
Study: NCT05852704
Drug: Placebo Tab
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
Study: NCT06046105
Drug: Administering intraperitoneal bupivacaine plus Ibuprofen for pain control after laparoscopic gynecological procedures
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Ibuprofen injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr.
Study: NCT05067153
Drug: Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
Normalized name: Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 days postoperative prophylactic treatment.
Study: NCT04662060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match acebilustat administered orally once daily
Study: NCT05630989
Drug: combination therapy with MEKi.
Approvals — FDA: no, EMA: no, PMDA: no
Description: This cohort will receive combination therapy with MEKi.
Study: NCT06007222
Drug: Non-antithrombotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic agents will be administered after randomization until the end of the study period.
Study: NCT05243563
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: self-applied topical steroid therapy using clobetasol propionate 0.05%
Study: NCT04494451
Drug: Vit C
Normalized name: M-Vit Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day
Study: NCT04494451
Drug: Standard medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv antibiotics alone
Study: NCT05740475
Drug: 9MW3811 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenously infused on day 1
Study: NCT05740475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo intravenously infused on day 1
Study: NCT06122181
Drug: HS-10384-matched placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing of HS-10384-matched placebo orally in a fasting state
Study: NCT04972981
Drug: ADCT-901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05585307
Drug: bavtavirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05585307
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05585307
Drug: Standard of Care (Substudy 01)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
Study: NCT05585307
Drug: Standard of Care (Substudy 03)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy, administered orally
Study: NCT05686863
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil
Study: NCT03612466
Drug: Neupogen Injectable Product
Normalized name: Neupogen Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
Study: NCT04756622
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
Study: NCT04799743
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
Study: NCT04854759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, capsule
Study: NCT05275465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different dose levels of placebo
Study: NCT06369961
Drug: transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adult cancer pain patients switched from oral opioid to TDF
Study: NCT04844619
Drug: 4mg/ml KDR2-2 suspension eyedrop
Approvals — FDA: no, EMA: no, PMDA: no
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.
Study: NCT05911126
Drug: Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet form received prior to the procedure
Study: NCT04844619
Drug: 16mg/ml KDR2-2 suspension eyedrop
Approvals — FDA: no, EMA: no, PMDA: no
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.
Study: NCT06202703
Drug: Pneumococcal Vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccination with pneumococcal vaccine (PCV13)
Study: NCT06364787
Drug: Targeted drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
Study: NCT04683796
Drug: 100% Autologous serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes. The tubes will be left standing in an upright position for 1-2 hours to enable blood clot formation at room temperature (18-25 C). The tubes will be centrifuged at 3000 g for 30 minutes at 20 C. The supernatant serum will be aseptically transferred into a sterile syringe to enable filtration through a 0.2 µm pore size membrane filter under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
Study: NCT04243629
Drug: Rapid-Acting Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novorapid or Humalog insulin delivered in a basal-bolus manner.
Study: NCT04243629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) delivered in a basal-bolus manner at a fixed ratio with insulin.
Study: NCT04706897
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
Study: NCT06148103
Drug: Patients who received Dexmedetomodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
Study: NCT06148103
Drug: patients who received propofol-fentanyl
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
Study: NCT05978518
Drug: CPM Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily device use
Study: NCT04931368
Drug: Control intervention: four courses of MATRix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive four courses of MATRix as induction treatment.
Study: NCT05959759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with the same appearance (color, taste, size, shape), 30 patients for this arm.
Study: NCT05544591
Drug: 611 Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
Study: NCT05544591
Drug: 611 Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
Study: NCT05544591
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
Study: NCT05133323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
Study: NCT05484414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Study: NCT05816772
Drug: Endosequence Bio ceramic Sealer
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brasseler,USA, a nano-particulate injectable premixed bioceramic sealer that contains Calcium Silicates, Calcium Phosphate, Calcium Hydroxide and Zirconium Oxide
Study: NCT05681403
Drug: Improved BEAM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
Study: NCT06418113
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
Study: NCT05266040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
Study: NCT04766723
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT04766723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT04682860
Drug: Hyoscine N Butylbromide
Normalized name: Hyoscine N butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis
Study: NCT06380205
Drug: Levonorgestrel/Ethinyl estradiol
Normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel/Ethinyl estradiol will be administered at protocol defined dose.
Study: NCT05461170
Drug: NRTI
Normalized name: Nucleoside Reverse Transcriptase Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI given orally.
Study: NCT04890548
Drug: AZD3427
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
Study: NCT04727528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plabeco comparator
Study: NCT05253794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet daily for 6 months
Study: NCT06233799
Drug: iPLB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once per three weeks injections of placebo
Study: NCT06233799
Drug: oPLB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral placebo tablets
Study: NCT06491355
Drug: mfolfox6 and hlx04 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
Study: NCT05963347
Drug: CHOP Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
Study: NCT06723171
Drug: IRX4204
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Treatment
Study: NCT00407017
Drug: Ketorolac LS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00407017
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00407017
Drug: EconoPred Plus
Normalized name: Econopred Plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06727630
Drug: PRJ1-3024
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRJ1-3024 is provided as capsules and is administered orally once a day
Study: NCT05057689
Drug: Intranasal Fentanyl (2 mcg/kg)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
Study: NCT05619653
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
Study: NCT05720559
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.4 mg/time, qd
Study: NCT05720559
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.
Study: NCT05161221
Drug: Naproxen 500 Mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will receive Naproxen 500 Mg post surgery for pain control
Study: NCT05161221
Drug: Tylenol Pill
Normalized name: Tylenol Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control
Study: NCT05113745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken twice daily
Study: NCT05227118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8189 matching placebo administered orally QD
Study: NCT05859711
Drug: saline mouth rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
Study: NCT03997097
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomised in the group placebo in 3 oral doses of per day
Study: NCT04481308
Drug: propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
Study: NCT06381180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant will be vaporized.
Study: NCT05532020
Drug: DCCR (diazoxide choline) extended-release tablets
Normalized name: choline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.
Study: NCT06158035
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06109415
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT06109415
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg
Study: NCT06109415
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g
Study: NCT06201039
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
Study: NCT02503163
Drug: KCT-0809 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no